Globus M, Bannet J, Lerer B, Belmaker R H
Psychopharmacology (Berl). 1982;78(1):81-4. doi: 10.1007/BF00470594.
Chronic treatment with dopamine (DA) agonists has been reported in various paradigms to cause supersensitivity of DA receptors or, contradictorily, subsensitivity of DA receptors. The present study administered 15 mg/kg bromocriptine for 7 days and measured both striatal spiperone binding and apomorphine (AP)-induced stereotypy. A significant decrease in AP-induced stereotypies was observed after chronic bromocriptine treatment, but without a significant parallel decrease in striatal spiperone binding. These results probably do not represent a true agonist-induced subsensitivity, but possibly show that residual bromocriptine in vivo may antagonize AP-induced stereotypy. Since some reports have suggested that L-Dopa may specifically reverse the increases in DA receptor number induced by chronic haloperidol, we also studied the effect of 7 days of L-Dopa treatment after 6-week chronic haloperidol treatment of mice. While chronic haloperidol significantly increased striatal spiperone binding, subsequent L-Dopa treatment did not reverse this biochemical supersensitivity. It is concluded that agonist induction of subsensitivity in the DA system is difficult to reproduce and may depend on highly specific dosage conditions and treatment schedules.
在各种实验范式中都有报道称,长期使用多巴胺(DA)激动剂会导致DA受体超敏,或者与之矛盾的是,导致DA受体低敏。本研究给予15mg/kg溴隐亭,持续7天,并测量纹状体舒必利结合以及阿扑吗啡(AP)诱导的刻板行为。长期溴隐亭治疗后,观察到AP诱导的刻板行为显著减少,但纹状体舒必利结合没有相应的显著下降。这些结果可能并不代表真正的激动剂诱导的低敏,而可能表明体内残留的溴隐亭可能拮抗AP诱导的刻板行为。由于一些报告表明左旋多巴可能特异性地逆转慢性氟哌啶醇诱导的DA受体数量增加,我们还研究了对小鼠进行6周慢性氟哌啶醇治疗后,给予7天左旋多巴治疗的效果。虽然慢性氟哌啶醇显著增加了纹状体舒必利结合,但随后的左旋多巴治疗并没有逆转这种生化超敏反应。得出的结论是,激动剂诱导DA系统低敏很难重现,可能取决于高度特定的剂量条件和治疗方案。